PPARG and familial pancreatic carcinoma: Given the above discussed antagonism of PPARγ activation against several carcinogenesis promoting pathways but also its antagonism to inflammation and fibrosis predisposing to cancer, PPARγ is a rational pharmacologic target in pancreatic cancer.